National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Panobinostat (Farydak®)

Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.


Rapid Review

Commenced Completed Outcome
26/01/2016 09/02/2016 Full Pharmacoeconomic Evaluation Recommended

 Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation